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Purpose—Black patients with diabetes are at greater risk for underuse of antidepressants even 
when they have equal access to health insurance. This study aims to evaluate the impact of 
removing a significant financial barrier to prescription medications (drug caps) on existing black-
white disparities in antidepressant treatment rates among patients with diabetes and comorbid 
depression.
Methods—We used an interrupted time series with comparison series (ITS) design and a 5% 
representative sample of all fee-for-service Medicare and Medicaid dual enrollees to evaluate the 
removal of drug caps on monthly antidepressant treatment rates. We evaluated the impact of drug 
cap removal on racial gaps in treatment by modeling the month-to-month white-black difference 
in use within age strata (<65, 65 or older). We compared adult dual enrollees with diabetes and 
comorbid depression living in states with strict drug caps (n=221) and without drug caps (n=1133) 
prior to the policy change.
Our primary outcome measures were the proportion of patients with any antidepressant use per 
month and the mean standardized monthly doses of antidepressants per month.
Findings—The removal of drug caps in strict cap states was associated with a sudden increase in 
the proportion treated for depression (4 percentage points; 95% Confidence Interval: 0.03, 0.05, 
<0.0001) and in the intensity of antidepressant use (SMD: 0.05; 95% CI: 0.03, 0.07, p<0.001). 
While antidepressant treatment rates increased for both whites and blacks, the white-black 
treatment gap increased immediately after Part D [0.04 percentage points; 95% CI: 0.01, 0.08] and 
grew over time [0.04 percentage points per month (0.002, 0.01); P<0.001].
Implications—Policies that remove financial barriers to medicines may increase depression 
treatment rates among patients with diabetes overall while exacerbating treatment disparities. 
Tailored outreach may be needed to address non-financial barriers to mental health services use 
among African Americans with diabetes.
INTRODUCTION
Diabetes affects more than 25 million Americans, costs an estimated $245 billion per year in 
health care costs and lost productivity, and is a major contributor to racial and ethnic 
disparities in morbidity and mortality.(1,2) More than half of adults with diabetes have at 
least one other chronic physical or mental health condition.(3) Depression is one of the most 
prevalent comorbidities, with an estimated 20% of adult diabetes patients suffering from 
major depression.(4)
Comorbid depression is independently associated with poorer outcomes among individuals 
with diabetes.(5–7) Identifying and treating depression has become an increasingly 
important component of diabetes management.(8) While antidepressant medications are 
highly effective tools in the co-management of depression among adults with diabetes, rates 
of pharmacologic treatment of depression remain suboptimal and are especially low among 
African Americans.(9,10)
The reasons for these differences likely include patient preferences for psychotherapy versus 
medications, stigma associated with depression, variation in care quality, competing 
demands, differences in prescribing, and out of pocket medication costs.(11–14) Previous 
Adams et al. Page 2













studies suggest that African Americans may be at greater risk for cost-related non-adherence 
and that reducing economic barriers to prescription drugs may reduce disparities in 
adherence to chronic disease medications.(15,16) Natural experiments that increase 
economic access to prescription drugs provide a unique opportunity to evaluate the degree to 
which such policy changes may reduce disparities in antidepressant treatment among 
diabetes patients.
When Medicare Part D was implemented as an outpatient prescription benefit for Medicare 
enrollees in 2006, seven million people who were dually enrolled in both Medicare and 
Medicaid due to permanent disability or low income were automatically transitioned from 
Medicaid drug coverage to Part D.(17,18) For dual enrollees living in states with strict caps 
on the number of reimbursable prescriptions per month (drug caps), the transition to Part D, 
which disallowed drug caps, eliminated a significant financial barrier to drug treatment.(19) 
Our central research question was whether the transition to Part D increased antidepressant 
treatment rates among dual enrollees with diabetes and depression living in states with strict 
drug caps at the time of the transition relative to those living in states without drug caps. 
Secondarily, we examined whether there were differences in response by race, in order to 
assess the potential for such policies to reduce disparities in antidepressant treatment among 
diabetes patients.
We hypothesized that the transition would increase overall rates of treatment of depression 
and reduce the racial disparity in antidepressant use. The findings from this study are highly 
relevant as newly eligible dual enrollees continue to transition from states with restrictive 
drug caps to Medicare Part D on an ongoing basis following the two-year waiting period for 
Medicare eligibility. In addition, they have the potential to inform evaluation of Medicaid 
coverage expansion under the Affordable Care Act and the need to assess the impact of the 
ACA on disparities populations. Specifically, the findings from this study provide 
information about the potential for reducing out-of-pocket costs for medications as a 
strategy to address under-treatment among patients with diabetes and as a mechanism to 
reduce racial disparities in depression treatment.
RESEARCH DESIGN AND METHODS
We used an interrupted time series with comparison series (ITS) design to examine changes 
in the monthly rate of antidepressant treatment for 24 months before and after the transition 
of dual enrollees from Medicaid to Medicare Part D drug coverage. This quasi-experimental 
design provides strong evidence of the immediate and ongoing effects of Part D on 
antidepressant treatment among diabetes patients with comorbid depression.
Our study protocol was reviewed and approved by the Institutional Review Board of the 
Kaiser Foundation Research Institute.
Data Sources and Study Population
We used a 5% nationally representative sample of dual Medicare and Medicaid enrollees 
provided by the Centers for Medicare and Medicaid Services. These data contain all health 
insurance claims and enrollment data between January 2004 and December 2007.(20,21) 
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Using these data, we identified a cohort of fee-for-service dual beneficiaries who were at 
least 18 years old in 2004 and who had at least one hospital diagnosis or two physician 
diagnoses (no more than 12 months apart) of diabetes (International Classification of 
Diseases, ICD9: 250.XX) (22) at any time during the study period (2004–2007). We 
excluded enrollees residing in Ohio, Arizona, and Louisiana due to data anomalies such as 
concurrent changes in coding and reporting methods.(23) The resulting population included 
60,288 adults with diabetes.
In order to ensure stable population characteristics over time and complete data on 
utilization, we also required continuous enrollment for at least 10 months per year in fee-for-
service Medicaid and Medicare during the study period (n=29,373) and excluded patients 
with more than 90 consecutive days in any year in an institution such as a nursing home 
(n=22,774).
Drug Reimbursement before Part D
We assigned strict drug cap status to four states (Texas, Oklahoma, Mississippi, Arkansas) 
that consistently limited monthly drug coverage to five or fewer total prescriptions or to 
three or fewer brand name drugs during the 24-month baseline period 2004–2005. We 
excluded from analysis 11 states where true exposure to or enforcement of drug caps was 
uncertain. For example, some states required caps, but allowed for exceptions for chronic 
disease medications. We conducted sensitivity analysis to assess the impact of excluding 
these 11 states and found that rates of medication use in the excluded states mimicked those 
of the no drug cap group. In addition, we excluded Tennessee, which instituted a strict drug 
cap late in the baseline period.(24)
We identified a comparison subgroup of dual enrollees who lived in 31 states (AK, CO, CT, 
DE, FL, HI, IA, ID, IN, MA, MD, MI, MN, MO, MT, ND, NE, NH, NJ, NM, NV, OR, RI, 
SD, UT, VA, VT, WA, WI, WV, WY) and the District of Columbia where there were no 
prescription drug caps during the 24-month baseline period. The strict drug cap and no drug 
cap states included 10,992 adults diagnosed with diabetes. Enrollees in our sample were 
similar to the overall fee-for-service dual enrollee population at the time with respect to race 
and ethnicity distribution, but slightly more likely to be under 65 (40% vs. 36%) and female 
(70% vs. 62%).(25)
Comorbid Major Depression
Within the cohort of 10,992 adult dual enrollees with diabetes, we identified a subset of 
people with evidence of major depression, defined as having at least one hospital or two 
physician visits with a diagnosis of major depression.(26) The resulting 1,354 dual enrollees 
with diabetes and comorbid major depression, representing 27,080 dual enrollees, served as 
the analytic cohort for this paper. (Figure 1)
Outcomes
Our primary outcomes were (1) the monthly proportion of patients with any use of 
antidepressants, including tricyclics, selective serotonin reuptake inhibitors, monoamine 
oxidase inhibitors, serotonin modulators, and selective norepinephrine reuptake inhibitors, 
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and (2) the intensity of use of these medications as represented by standardized monthly 
doses. To assess intensity of use, we first defined a standardized monthly dose (SMD) 
(27,28) for each unique molecular entity of interest, which was equal to the median number 
of milligrams dispensed per month across person-months with any use during the entire 
study period. Thus, SMDs represent the population’s “typical” monthly dose for a given 
medication in this population. We then calculated average SMDs dispensed per patient per 
month across all antidepressant medications.
Policy Variables
We controlled for prior trends in the outcomes of interest using segmented time series 
regression, as described in previous studies.(19,27,29–31) We included a dichotomous 
indicator for months before and after Part D implementation, as well as a variable to 
estimate changes in post-Part D trends. We identified state drug cap status in 2005 (strict 
drug cap vs. no drug cap) using a dichotomous indicator. We then estimated the effect of 
Part D within strict cap and no cap states, separately.
Covariates
We used Medicare administrative files to determine racial identity, age, and gender. Given 
higher rates of long-term disability among younger dual enrollees, we stratified all analyses 
by age: aged 65 or older (elderly) versus 18–65 years of age (non-elderly). Only black and 
white dual enrollees are included in this analysis due to the lack of sensitivity and specificity 
for other racial and ethnic categories during the study period.(32, 33)
Statistical Analysis
We used interrupted time series (ITS) with comparison series to evaluate changes from 
baseline in the level and trend of antidepressant use.(30) Segmented regression analysis of 
interrupted time series data allowed us to evaluate the immediate discontinuity and longer 
term slope change in medication after the introduction of Part D. In these models, potential 
confounding was limited to factors that were both correlated with the outcome and that 
changed at the same time as the intervention. Therefore, factors that changed gradually over 
time such as age, education, income and comorbidity were not potential confounders and 
were not included in the regression models. (30)
We first estimated the overall impact of transitioning to Part D by cap status using separate 
ITS models for dual enrollees with major depression in strict drug cap and no drug cap 
states. To control for anticipatory effects of the policy (e.g., changes in prescribing 
practices) and the phase-in period of the transition, we excluded the observations between 
December 2005 and March 2006. Our time series models controlled for autocorrelation by 
testing for first-order autoregressive processes and correcting for significant correlations. 
We also tested for non-linearity of the models.(30)
We next examined changes in rates of antidepressant use and in intensity of use, stratifying 
by black and white race within non-elderly (under 65) and elderly (65+) subgroups. We then 
directly evaluated the impact of Part D on racial gaps in treatment by modeling the month-
to-month white-black difference in use within age strata.
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All statistical analyses were conducted using the SAS system (SAS, v.9.0, Durham, NC).
(34)
RESULTS
Baseline Characteristics by Depression Status
Table 1 examines the characteristics of dual enrollees with diabetes at baseline (2005) 
overall and compares demographic characteristics between patients with and without 
evidence of diabetes and comorbid major depression during the study period. Dual enrollees 
with a major depression diagnosis were more likely to be white, under the age of 65, and 
female compared to those without concurrent depression. In addition, those with diagnoses 
of comorbid major depression were more likely to be living in states without drug caps prior 
to Part D.
Impact of Part D on Antidepressant Use in States with and without Drug Caps
At baseline (Table 2), the proportion using antidepressants in states without drug caps was 
more than twice that for an equivalent population of dual enrollees living in strict cap states.
[11% (cap) vs. 28% (no cap), November 2005] The transition to Part D was associated with 
a statistically significant increase in the proportion of antidepressant users in drug cap states 
(4 percentage points; 95% Confidence Interval: 0.03, 0.05, <0.0001) and an increasing trend 
in this proportion post policy (0.1 percentage points per month (0.0002, 0.001), p=0.01).
(Figure 2) The estimated relative increase over the value predicted by baseline trend in the 
proportion of patients using any antidepressants at 12 months post Part D implementation 
(December 2007) was 45%. There was a corresponding small decrease in the proportion of 
people with any use in no drug cap states (−1 percentage point; 95% CI: −0.01, −0.003; 
p=0.007) and a slight declining trend post policy (−0.05 percentage points per month; 95% 
CI: −0.001, −0.0001, p=−0.026) in these states. The corresponding relative decrease in use 
at 12 months post Part D was 3%.
Dual enrollees in strict drug cap states also experienced a one-time increase in the 
standardized monthly dose of antidepressant use (SMD: 0.05; 95% CI: 0.03, 0.07, p<0.001), 
but no change was observed among dual enrollees in no drug cap states (SMD: −0.002; 95% 
CI: −0.02, 0.01, p=0.828), although we observed a slightly declining trend in the intensity of 
use in those states post policy (−0.002 standard monthly doses per month; 95% CI: −0.003, 
−0.0005, p=0.005). At 12 months post Part D implementation, mean SMD per month within 
strict cap states increased 25% relative to what would have been predicted according to 
baseline trends. Within no drug cap states, there was an estimated 4% decrease in the mean 
SMD per month relative to baseline.
Racial Differences in Antidepressant Use Pre and Post Policy in Cap States
Prior to the policy change, the observed proportion of depressed patients using 
antidepressants in strict cap states was half as much for blacks compared to whites.(Figure 
3A) The Part D transition was associated with an increase in the proportion treated among 
whites [non-elderly: 0.08 percentage points; 95% CI: 0.06, 0.11; elderly: 0.03 percentage 
points; 95% CI: 0.02, 0.04] and blacks [non-elderly: 0.04 percentage points; 95% CI: 
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0.002,0.01; elderly: 0.04 percentage points; 95% CI: 0.03,0.04] in strict drug cap states, that 
was not observed among dual enrollees living in states without drug caps.(Table 3, Columns 
2–4) The greater increase among white non-elderly dual enrollees in strict cap states resulted 
in a statistically significant increase in the gap between white and black patients [0.04 
percentage points; 95% CI: 0.01, 0.08] This gap grew gradually wider during the post-Part D 
period [0.04 percentage points per month (0.002, 0.01); P<0.001].
In contrast, following Part D, there was a slight reduction in the treatment gap between 
white and black non-elderly dual enrollees in no drug cap states [−0.02 percentage points; 
95% CI: −0.03, −0.01] due to a decrease in the proportion treated among whites [−0.01; 
95% CI: −0.02, −0.004]. The treatment gap continued to decline over time among elderly 
dual enrollees in no cap states [−0.01 percentage points per month; 95% CI: −0.001, 
−0.00004; p<0.05].
Changes in the intensity of use by race are presented in Figure 3B and Table 3, Columns 5–
7. Part D was associated with an increase in the intensity of use for both white [non-elderly: 
0.12 SMDs; 95% CI: 0.09, 0.15; elderly: 0.03 SMDs; 95% CI: 0.0002, 0.06] and black [non-
elderly: 0.05 SMDs; 95% CI: 0.01, 0.09; elderly: 0.03 SMDs; 95% CI: 0.02, 0.03] dual 
enrollees in drug cap states, regardless of age. The magnitude of change was greatest among 
non-elderly whites [0.12 SMDs; 95% CI: 0.09, 0.15], resulting in a statistically significant 
increase in the gap between racial groups of 0.10 standard monthly doses at the time of the 
policy [95% CI: 0.03, 0.16]. No statistically significant changes in level or trend in the 
intensity of use of antidepressants were observed among dual enrollees in non-drug cap 
states with the exception of a decrease among black elderly patients at the time of the policy 
[−0.02 SMDs; 95%CI: −0.04. −0.01].
DISCUSSION
Among dual enrollees with diabetes and comorbid major depression living in states with 
drug caps, we observed a modest increase in the proportion using antidepressants and in the 
intensity of antidepressant use after the transition to Part D. The absence of a corresponding 
increase in use in non-drug cap states is consistent with our hypothesis that the removal of 
drug caps under Part D would be associated with an increase in access to antidepressant 
therapy. However, we also observed an unexpected increase in the racial gap in 
antidepressant use among dual enrollees with diabetes and major depression in strict drug 
cap states immediately following Part D implementation that was driven by a greater 
response to the policy among non-elderly whites.
Two previous studies of Part D effects reported no changes in medication use associated 
with Part D among elderly dual enrollees.(35,36) Differences between our work and 
previous studies of changes in utilization may be explained by our focus on those living in 
states with strict drug caps. In addition, we observed a slight decrease in use within non-drug 
cap states; combining all dual enrollees without regard to coverage changes would lead to a 
conclusion of no change at the population level.
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To our knowledge, our study is the first to show an increase in the racial gap in 
antidepressant treatment associated with Medicare Part D implementation. In a related study, 
we reported that Part D was equally effective in increasing the use of lipid lowering 
medications among black and white dual enrollees with diabetes.(37) The reasons for 
differential response to coverage expansion are likely multifactorial. One possible 
explanation for this difference is that use among African Americans may be driven by non-
financial factors to a greater extent than it is among whites..(38) For example,, several 
studies have reported cultural differences in preferences for mental health treatment and 
illness-related beliefs that may contribute to reduced price sensitivity among African 
Americans.(3,11) In addition, differences in knowledge of coverage changes, may also 
contribute to the observed differential policy response.(39) For example, Haviland and 
colleagues reported that African Americans, Hispanics and Asian Pacific Islanders were all 
more likely to report lack of knowledge about Part D plan coverage.(40) More studies are 
needed to identify the potential mechanisms for differential response in order to identify 
mediating factors that are potentially modifiable through health system intervention (e.g., 
knowledge gaps).
This quasi-experimental study has some limitations that deserve consideration. During the 
study period, there were other changes in Medicaid and Medicare coverage and utilization 
management that may have contributed to the observed changes. By our design, we focused 
on a population of dual enrollees who experienced a substantial change in exposure to drug 
caps for simplicity of analysis and because caps are known to have especially strong effects.
(9,27,29) We limited analysis to enrollees who had evidence of major depression during the 
study period. Since antidepressants may be used for other indications, this allowed us to 
focus on a more homogenous population. However, our findings may apply to the treatment 
of milder forms of depression as well that are not as reliably identified in claims data. In 
addition, with the exception of black and white dual enrollees, race and ethnicity data in 
Medicaid are generally unreliable for the period of this study. As a result, we did not include 
subgroups other than blacks and whites in our comparison of race differences in use, nor 
could we accurately exclude dual enrollees of Hispanic origin from our comparisons. 
Therefore, there may have been additional variation in response in these subgroups that we 
failed to capture. Allowing beneficiaries to have a diagnosis at any time during the study 
period means that some patients included in the denominator at any given time may have 
been ineligible for treatment. However, this error should be distributed equally across 
subgroups of patients and change gradually over time, and is therefore unlikely to have 
introduced bias in our findings. Finally, our observations of a study population living in 
selected states with substantial financial barriers in Medicaid drug coverage do not 
necessarily reflect the experience of the entire dual enrollee population.
CONCLUSION
Depression is frequently undertreated among patients with diabetes and African Americans 
may be at higher risk for under-treatment of this high cost and potentially disabling 
comorbidity.(9,10) Inadequate medication coverage poses a significant barrier to treatment 
for many patients, particularly low income Medicaid beneficiaries.(12–14) In this natural 
experiment, we demonstrated the potential for expanded drug coverage to improve rates of 
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antidepressant use. However, coverage expansions may also have the unintended 
consequence of widening racial disparities in antidepressant treatment. The ongoing 
transition of dual enrollees from state Medicaid drug coverage to Medicare Part D programs 
following a two-year waiting period may perpetuate these disproportionate impacts in 
certain states.(18) At a minimum, federal and state health systems leaders should be aware 
of the potential for unintended effects of coverage expansions for disparities reduction. 
Interventions at the point of care may be needed to counteract these effects through 
increased education and outreach to African Americans with diabetes about the importance 
of depression treatment as a component of diabetes care.
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Figure 2. Changes in the Prevalence of Antidepressant Use Before and After Part D by Drug 
Cap Status*
*Monthly Prevalence (A) and Intensity of Antidepressant Use (B) Before and After the 
Transition from Medicaid to Part D among Dual Enrollees with Diabetes and Co-Morbid 
Major Depression in Strict Drug Cap Compared to No Drug Cap States; Solid black 
circle=observations in drug cap states; solid black line=estimated utilization in drug cap 
states from time series models; Black dashed line=predicted utilization in drug cap states 
based on baseline trends; Open grey circle=observations in non-drug cap states; solid grey 
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line=estimated utilization in non-drug cap states from time series models; Black dashed 
line=predicted utilization in non-drug cap states based on baseline trends
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Figure 3. Changes in the Prevalence and Intensity of Antidepressant Use among Dual Enrollees 
Pre and Post Part D in States with Drug Cap by Race*
*Monthly Prevalence (A) and Intensity of Antidepressant Use (B) Before and After the 
Transition from Medicaid to Part D among Black and White Dual Enrollees with Diabetes 
and Co-Morbid Major Depression in Strict Drug Cap States Only; Solid black 
diamond=observed utilization of black patients; solid black line=estimated utilization for 
black patients from time series model; Open grey square=observed utilization of white 
patients; solid grey line=estimated utilization for white patients from time series model; 
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dotted black line=estimated difference in utilization between whites and blacks from time 
series models
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